Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

NARecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2029

Conditions
COPDEmphysema
Interventions
DEVICE

Apreo BREATHE Airway Scaffold

The experimental treatment involves placement of up to 6 Apreo BREATHE Airway Scaffolds (up to 3 per lung), in a single procedure using bronchoscopy and fluoroscopy. Treatment group subjects will also receive optimal medical management (OMM).

OTHER

Optimal Medical Management (OMM)

Subjects will receive optimal medical management tailored to patient needs and per standard of care and as outlined in the 2024 GOLD report. This may include smoking cessation, vaccination, long-acting bronchodilator therapy, corticosteroids (when appropriate), and participation in or maintenance of an exercise program or pulmonary rehabilitation program.

Trial Locations (13)

15801

RECRUITING

Clinical Research Associates of Central Pennsylvania, DuBois

19140

RECRUITING

Temple University, Philadelphia

32224

RECRUITING

Mayo Clinic, Jacksonville

32806

RECRUITING

Orlando Health, Orlando

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

43210

RECRUITING

The Ohio State University, Columbus

44103

RECRUITING

Cleveland Clinic Foundation, Cleveland

48109

RECRUITING

University of Michigan, Ann Arbor

60637

RECRUITING

University of Chicago, Chicago

66160

RECRUITING

University of Kansas Medical Center Research Institute, Kansas City

85234

RECRUITING

Banner Health, Gilbert

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

9713 GZ

RECRUITING

University Medical Center Groningen, Groningen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Apreo Health, Inc.

INDUSTRY